Determinants of cellular sensitivity to topoisomerase-targeting antitumor drugs
- PMID: 8996605
- DOI: 10.1016/s1054-3589(08)61135-7
Determinants of cellular sensitivity to topoisomerase-targeting antitumor drugs
Abstract
It is now clear that topoisomerase activity level is an important determinant of sensitivity to topo drugs. The regulation of topoisomerases is no doubt complex and multifaceted and is probably accomplished through redundancy at many control levels. The mechanism(s) of altered topo I expression in certain tumor types is unknown, but may be related to the central importance of topoisomerases in proliferating cell functions (transcription, replication, etc.), and the aberrant and chronic activation of these functions as a result of specific tumorigenic alterations. Small differences in sensitivity to chemotherapy can have a dramatic effect on cure rates, and therefore subtle cell type-specific differences may be important determinants of drug sensitivity. Whether abnormal topoisomerase quantity and specific activity are associated with resistance or sensitivity to topoisomerase-targeted chemotherapy in the clinic is now being studied. Determinants downstream of cleavable complex formation that affect the sensitivity of tumor versus normal cells to topo drugs in particular and DNA-damaging agents in general are little known. The goal of enhancing selective tumor cell killing relative to the normal cells that are dose limiting may be achieved either by overcoming tumor cell resistance or by protecting normal cells. Both of these strategies will become more feasible as specific molecular differences between tumor and normal cells are being rapidly identified and new combination therapies that take advantage of these differences are being designed and tested.
Similar articles
-
Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.Curr Med Chem. 2010;17(35):4270-90. doi: 10.2174/092986710793361252. Curr Med Chem. 2010. PMID: 20939813 Review.
-
Clinical resistance to topoisomerase-targeted drugs.Biochim Biophys Acta. 1998 Oct 1;1400(1-3):275-88. doi: 10.1016/s0167-4781(98)00141-9. Biochim Biophys Acta. 1998. PMID: 9748627 Review.
-
Topoisomerases, new targets in cancer chemotherapy.Med Oncol Tumor Pharmacother. 1990;7(1):11-8. doi: 10.1007/BF03000485. Med Oncol Tumor Pharmacother. 1990. PMID: 2160032 Review.
-
The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.Carcinogenesis. 1993 Sep;14(9):1759-63. doi: 10.1093/carcin/14.9.1759. Carcinogenesis. 1993. PMID: 8403196
-
[Poisons of DNA topoisomerases I and II].Bull Cancer. 1993 Nov;80(11):923-54. Bull Cancer. 1993. PMID: 8081034 Review. French.
Cited by
-
Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity.J Cell Biol. 1996 Aug;134(3):757-70. doi: 10.1083/jcb.134.3.757. J Cell Biol. 1996. PMID: 8707853 Free PMC article.
-
Elucidating the molecular mechanisms underlying the induction of autophagy by antidepressant-like substances in C57BL/6J mouse testis model upon LPS challenge.Cell Commun Signal. 2023 Sep 21;21(1):251. doi: 10.1186/s12964-023-01270-6. Cell Commun Signal. 2023. PMID: 37735683 Free PMC article.
-
Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks.Nucleic Acids Res. 2003 Aug 1;31(15):4373-84. doi: 10.1093/nar/gkg497. Nucleic Acids Res. 2003. PMID: 12888496 Free PMC article.
-
Mms22p protects Saccharomyces cerevisiae from DNA damage induced by topoisomerase II.Nucleic Acids Res. 2005 Feb 17;33(3):1021-30. doi: 10.1093/nar/gki246. Print 2005. Nucleic Acids Res. 2005. PMID: 15718301 Free PMC article.